Show Notes
For years, AI in drug discovery has been a promise—billions invested, hundreds of papers published, dozens of startups founded, but actual drugs coming out the other end? Not yet. This is changing in 2026. Several AI-discovered drug candidates are now entering mid-to-late stage clinical trials. This is the year the receipts arrive for AI in drug discovery. The biotech industry is calling 2026 a landmark year. For a sector that's been hyped as much as it's been scrutinized, the fact that we're finally getting real clinical data on AI-designed drug candidates is a big deal. Multiple candidates discovered and optimized using AI systems are now in Phase 2 and Phase 3 clinical trials, primarily focused on oncology and rare diseases—areas where existing options are limited and financial incentives for innovation are high. Companies furthest along include Insilico Medicine, Recursion Pharmaceuticals, and Exscientia. Their drug candidates were identified by AI systems analyzing massive biological datasets and predicting molecular structures likely to interact with disease targets in useful ways. What used to take teams of medicinal chemists years to accomplish, these systems can explore in weeks—a massive boost for clinical trial phases by reducing R&D time. Why this matters: Traditional drug discovery takes 10-15 years and over $1 billion per approved drug. Most candidates fail—the attrition rate in clinical trials is brutal. AI's promise is dramatically improving the hit rate by better predicting which candidates will actually work before spending money on trials. Even a modest improvement in clinical trial success rates would have enormous downstream impact on human health. But 2026 is a stress test. Clinical trials expose whether AI-predicted drug behavior holds up in actual human biology, which is extraordinarily complex. AI models are trained on known data; when candidates reach trials, you're testing the model's ability to generalize to real biological complexity that wasn't in training. Early signals have been mixed—some candidates performing well, others hitting unexpected toxicity issues. The honest answer: we don't know yet how much AI improves success rates at the clinical stage. For data scientists interested in this space, the most interesting current work is in molecular property prediction, protein structure modeling building on AlphaFold, and multi-objective optimization across efficacy, safety, and synthesizability simultaneously. Recursion's operating system approach treats drug discovery as a data problem end-to-end—one of the most ambitious attempts to apply ML infrastructure thinking to biology at scale. AI in drug discovery is no longer just a story about potential—it's now a story about evidence. The next two years of clinical data will either validate or seriously challenge what's been claimed.
More from Data Science With Sam
Sam sits down with Dr. Zahra Timsah — co-founder and CEO of Igentic AI and author of The AI CEO — for a direct conversation about what AI is actually doing to leadership. Dr. Timsah holds a PhD in biochemistry and an MBA in strategy, has led AI transformation at IQBia, Mass Mutual, and GSK, and has advised the FDA and US Senate on AI policy. She's also one of the clearest voices making the case that the AI era is a particular opportunity for women who know how to seize it.
Sam sits down with Shawn Kercher — Co-Founder & CEO of HummingAgent.ai — to cut through the noise around AI agents. Shawn built his company on a simple but powerful observation: most AI products are just ChatGPT wrappers. HummingAgent is his answer — a full-custom software shop that builds private, in-environment AI workflows for companies that run on real data, messy CRMs, and processes that only exist in someone's head.
Shashank Akinapalli is a Senior Data Engineer at TCS where he leads cloud data lakehouse initiatives and real-time streaming architectures for supply chain intelligence. With 14 years of experience across IBM DataStage, Databricks, Snowflake, dbt, AWS, and Spark-based ecosystems, he has previously worked with USAA in banking and Blue Cross Blue Shield in healthcare. IN THIS EPISODE: ▪ The biggest architectural shift when migrating from IBM DataStage to a modern cloud lakehouse — and why the technical migration is the easier half, while reconstructing encoded business knowledge is the real challenge ▪ How to choose between Snowflake and Databricks: Databricks for heavy transformation and Python workloads, Snowflake for structured SQL and BI, and where dbt fits as the layer that eliminates repetitive SQL code ▪ The real UNFI example: how batch processing caused inventory misrepresentation (800 units sold, system still showing 1,000 available), and how real-time Databricks pipelines eliminated that problem and unlocked fraud detection on top ▪ Data governance across three regulated domains: the four pillars — data quality, redundancy, least-privilege access, and lineage — and the three questions every framework must answer first ▪ Why CI/CD transformed data engineering: from manual, multi-team deployments with risky rollbacks to automated quality checks, Git version control, and the specific silent failure that finally convinces a team to invest ▪ How the data engineer role shifts over the next three years: from pipeline development to data product engineering, from reactive operations to AI-predicted failure prevention, and from human dashboards to AI agents making autonomous predictions ▪ Practical advice for data engineers who want to stay relevant: Python, PySpark, cloud architecture, and understanding the full data lifecycle from ingestion to consumption
Karima Sharif-Ali — known affectionately in the industry as the Fresh Princess of Media — is the SVP of Strategic Accounts at Doceree, a platform transforming point-of-care communications for healthcare brands. Over her career, Karima has shaped the marketing journeys of more than 100 pharmaceutical and medical device brands across agencies including WPP, Publicis, and IPG MediaBrands. She is a thought leader featured in AdWeek and MM+M, co-founder of the Women of Color Affinity Group (now the Mosaic Collective Leadership), and a global board member of the Healthcare Businesswomen's Association. She holds an MBA from Rosemont College and a BA in Communications from Temple University.
Jim Spignardo is the Director of Cloud Strategy and AI Enablement at ProArch, a global IT services and consulting firm. With 25 years in IT spanning network engineering, cloud, cybersecurity, and strategic consulting, Jim advises executive teams on modernisation, operational resilience, and AI-enabled transformation that delivers measurable business value. He is the architect behind ProArch's Microsoft 365 Copilot adoption playbook, which has been deployed with clients across financial services, credit unions, and enterprise organisations. Jim is also the author of The AI Turning Point, available on Amazon, and publishes the Control All Innovate newsletter on LinkedIn, where he writes approximately three articles per week on AI strategy and adoption. IN THIS EPISODE: ▪ Why the through-line of Jim's 25-year career isn't the technology — it's the discipline of making technology actually work for the organisation and justifying that investment to leadership ▪ The real reasons 95% of enterprise AI pilots fail: weak use cases selected before the problem is clearly defined, and jumping to exciting initiatives without asking whether AI is actually the right solution ▪ Shadow AI — the hidden ROI nobody measures: employees quietly using AI tools on their own often deliver real productivity gains that never appear in official metrics, causing organisations to underestimate what AI is already doing ▪ What a successful Microsoft 365 Copilot rollout looks like in 90 days: a strong business case, a targeted pilot with the right stakeholders, measurable use cases, and no broad rollout before value is proven in a contained environment ▪ Why data governance should be an accelerator, not a blocker — good governance tells people what they CAN do, enables faster experimentation, and prioritises use cases so organisations operationalise value sooner ▪ AI amplifies broken processes and can't fix culture — if work processes were broken before AI arrived, AI will expose that faster than anything else ▪ What organisational readiness for AI actually requires: an AI governance council, internal champion programmes, and — critically — someone in the organisation with AI transformation as their primary job description, not a side project FIND JIM SPIGNARDO: LinkedIn: https://www.linkedin.com/in/spignardo/?skipRedirect=true Book: The AI Turning Point — available on Amazon ProArch: https://www.linkedin.com/company/proarch-it-solutions-pvt-ltd/ Website: https://www.proarch.com/